PATENT CLAIM ANALYSIS

Application Number: 15994999
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "093200"]

Abstract:
Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Claim (Index 61):
A method for identifying a patient capable of benefiting from gene therapy treatment for tumor lesions, and treating the patient in need of treatment thereof by decreasing tumor burden in the patient, the method comprising:\n a) administering a sufficient quantity of a first injection or infusion of a gene therapy retroviral vector particle comprising an HSV-thymidine kinase (HSV-TK) polynucleotide to a target tissue in the patient, and transducing cells from the target tissue with the polynucleotide encoding HSV-TK, thereby expressing HSV-TK in the transduced cells, wherein the HSV-TK polynucleotide encodes a mutated form of HSV-TK comprising a mutation at either amino acid residue 32 or 33, wherein the amino acid residues correspond to positions 32 and 33 of SEQ ID NO: 2, wherein amino acid residues 32 and 33 are each independently mutated to an acidic amino acid or to cysteine, and wherein the mutated form of HSV-TK increases cell kill activity relative to a wild-type thymidine kinase; b) administering to said patient a substrate of HSV-TK attached to a radioactive tracer; c) measuring the relative amount of radioactive tracer signal present in the target tissue; d) identifying if the level of radioactive tracer signal is above a certain threshold; e) determining the location of tumor lesions in the patient to determine whether the tumor lesion co-localizes with the measured radioactive tracer signal in step (c); and f) administering said patient with a second injection or infusion of the gene therapy retroviral vector particle comprising the HSV-TK polynucleotide comprising the nuclear export sequence of step a) and a substrate of HSV-TK that is not attached to a radioactive tracer for treatment if (i) the measured radioactive tracer signal of step (c) in the patient is above the certain threshold, and (ii) the location of the measured radioactive signal co-localizes with tumor lesions as in step (e); wherein the gene therapy retroviral vector particle is administered systemically, and wherein the administering of step f) treats the patient in need thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.275
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14214448', '14214522', '15892295', '10457604', '12319640']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6972136313238818
- 35 USC 102 Novelty (BERT): 0.6578787076758645
- Combined Prediction Score: 0.69328013895908
- Mean Citation Score: 416.24180000000007
- Max Citation Score: 628.63104
- Similarity Product: 610.5690994308471

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test